CN114173763A - 一种拉考沙胺药物组合物及其药物制剂 - Google Patents

一种拉考沙胺药物组合物及其药物制剂 Download PDF

Info

Publication number
CN114173763A
CN114173763A CN202080053128.8A CN202080053128A CN114173763A CN 114173763 A CN114173763 A CN 114173763A CN 202080053128 A CN202080053128 A CN 202080053128A CN 114173763 A CN114173763 A CN 114173763A
Authority
CN
China
Prior art keywords
lacosamide
sustained release
pharmaceutical composition
pharmaceutically acceptable
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080053128.8A
Other languages
English (en)
Inventor
吕少琼
李守峰
郑�勋
王众勤
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shanghai Aucta Pharmaceuticals Co Ltd
Original Assignee
Shanghai Aucta Pharmaceuticals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Aucta Pharmaceuticals Co Ltd filed Critical Shanghai Aucta Pharmaceuticals Co Ltd
Publication of CN114173763A publication Critical patent/CN114173763A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5089—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Medicinal Preparation (AREA)

Abstract

本发明涉及一种拉考沙胺药物组合物及其药物制剂。所述药物组合物包含缓释多颗粒，其中所述缓释多颗粒的每个包含：(a)载药核芯，其包含拉考沙胺或其药学上可接受的盐；和(b)包裹所述载药核芯的缓释层。本发明还提供一种口服一日一次的拉考沙胺缓释制剂。

Description

PCT国内申请，说明书已公开。

Claims (13)

  1. PCT国内申请，权利要求书已公开。
CN202080053128.8A 2019-06-06 2020-06-05 一种拉考沙胺药物组合物及其药物制剂 Pending CN114173763A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN201910490175 2019-06-06
CN2019104901758 2019-06-06
CN201911189496 2019-11-28
CN2019111894960 2019-11-28
PCT/CN2020/094556 WO2020244615A1 (zh) 2019-06-06 2020-06-05 一种拉考沙胺药物组合物及其药物制剂

Publications (1)

Publication Number Publication Date
CN114173763A true CN114173763A (zh) 2022-03-11

Family

ID=73609344

Family Applications (3)

Application Number Title Priority Date Filing Date
CN202080053128.8A Pending CN114173763A (zh) 2019-06-06 2020-06-05 一种拉考沙胺药物组合物及其药物制剂
CN202210082074.9A Active CN114404393B (zh) 2019-06-06 2020-06-05 一种拉考沙胺药物组合物及其药物制剂
CN202010504126.8A Active CN112043681B (zh) 2019-06-06 2020-06-05 一种拉考沙胺药物组合物及其药物制剂

Family Applications After (2)

Application Number Title Priority Date Filing Date
CN202210082074.9A Active CN114404393B (zh) 2019-06-06 2020-06-05 一种拉考沙胺药物组合物及其药物制剂
CN202010504126.8A Active CN112043681B (zh) 2019-06-06 2020-06-05 一种拉考沙胺药物组合物及其药物制剂

Country Status (5)

Country Link
US (2) US11337943B2 (zh)
EP (1) EP3981390A4 (zh)
CN (3) CN114173763A (zh)
CA (1) CA3148705A1 (zh)
WO (1) WO2020244615A1 (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114699368A (zh) * 2022-04-12 2022-07-05 南京海纳医药科技股份有限公司 一种拉考沙胺口服溶液及其制备方法

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114983973B (zh) * 2022-05-31 2023-05-05 石家庄四药有限公司 一种乌拉地尔缓释胶囊及其制备方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10786464B2 (en) * 2009-11-03 2020-09-29 Lupin Limited Modified release formulation of lacosamide
WO2011101863A2 (en) * 2010-02-19 2011-08-25 Cadila Healthcare Limited Extended release pharmaceutical compositions of lacosamide
BR112013013525A2 (pt) 2010-12-02 2016-10-18 Ucb Pharma Gmbh formulação de liberação controlada sólida de lacosamida para administração oral, composição farmacêutica sólida, e, método para a prevenção, alívio e/ou tratamento de uma doença do sistema nervoso central
CN102920663B (zh) * 2011-08-08 2015-02-11 丽珠医药集团股份有限公司 一种泛昔洛韦缓释微丸、其制备方法及应用
CN102670544B (zh) * 2012-06-05 2016-04-06 石家庄四药有限公司 一种拉科酰胺缓释片及其制备方法
CN102885796A (zh) * 2012-07-30 2013-01-23 永光制药有限公司 一种治疗癫痫的拉科酰胺片剂及其制备方法
EP3102190A4 (en) * 2014-02-07 2017-09-06 Auspex Pharmaceuticals, Inc. Novel pharmaceutical formulations
EP3258921A1 (en) * 2015-02-20 2017-12-27 UCB Biopharma SPRL Combination treatment
BR112018012870A2 (pt) * 2015-12-30 2018-12-04 Adamas Pharmaceuticals Inc métodos e composições para o tratamento de transtornos relacionados à crise
CN105534949A (zh) * 2016-01-06 2016-05-04 北京修正创新药物研究院有限公司 一种盐酸度洛西汀的肠溶微丸制剂
CN106619531A (zh) * 2016-10-02 2017-05-10 上海奥科达生物医药科技有限公司 一种稳定的口服缓释混悬剂的制备方法
KR102083241B1 (ko) * 2018-02-14 2020-03-02 환인제약 주식회사 라코사미드를 함유하는 약제학적 서방성 조성물

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114699368A (zh) * 2022-04-12 2022-07-05 南京海纳医药科技股份有限公司 一种拉考沙胺口服溶液及其制备方法

Also Published As

Publication number Publication date
US20220280456A1 (en) 2022-09-08
EP3981390A1 (en) 2022-04-13
CA3148705A1 (en) 2020-12-10
CN114404393A (zh) 2022-04-29
CN114404393B (zh) 2023-02-24
WO2020244615A1 (zh) 2020-12-10
EP3981390A4 (en) 2023-01-25
US11337943B2 (en) 2022-05-24
CN112043681A (zh) 2020-12-08
CN112043681B (zh) 2022-04-12
US11883374B2 (en) 2024-01-30
US20210283076A1 (en) 2021-09-16

Similar Documents

Publication Publication Date Title
CA2348090C (en) Oral pulsed dose drug delivery system
EP1940361B1 (en) Pharmaceutical dosage forms having immediate release and/or controlled release properties
US20220062204A1 (en) Methods and compositions for the treatment of seizure-related disorders
PL200816B1 (pl) Powleczony rdzeń o opóźnionym uwalnianiu dający impuls czasowy uwalniania i farmaceutyczna postać dawkowana
SK9899A3 (en) Tramadol multiple unit formulations
CZ303495B6 (cs) Mnohocásticový modifikovane uvolnující prostredek a jeho použití, pevná orální dávkovací forma
AU2004289223A1 (en) Once daily dosage forms of trospium
CN112043681B (zh) 一种拉考沙胺药物组合物及其药物制剂
CA3021071A1 (en) Oral pharmaceutical compositions of mesalazine
MXPA06008854A (es) Mini tabletas de clorhidrato de venlafaxina de liberacion prolongada recubiertas.
US20070092568A1 (en) Galantamine compositions
EP2994112A1 (en) Modified release pharmaceutical compositions of dexmethylphenidate or salts thereof
CA2984235C (en) Rivastigmine-containing sustained-release pharmaceutical composition
EP2736496B1 (en) Pharmaceutical composition containing an antimuscarinic agent and method for the preparation thereof
US20240041803A1 (en) Lacosamide pharmaceutical composition and dosage form thereof
WO2011027322A1 (en) Extended release dosage form containing olopatadine for oral administration
MX2008004282A (en) Pharmaceutical dosage forms having immediate release and/orcontrolled release properties
MXPA06004017A (es) Formas de dosis una vez al dia de trospio

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40063013

Country of ref document: HK

SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information
CB02 Change of applicant information

Address after: No.10, Lane 100, Banxia Road, Pudong New Area, Shanghai, 201318

Applicant after: Shanghai Aokeda Pharmaceutical Technology Co.,Ltd.

Address before: No.10, Lane 100, Banxia Road, Pudong New Area, Shanghai, 201318

Applicant before: SHANGHAI AUCTA PHARMACEUTICALS Co.,Ltd.